GlobeNewsWire
14 Nov 2025, 18:25 UTC · 43w ago
Verdict
Headline leans bearish. We score ALVO −1.00 across four claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
4 claims · scored −1 bearish … +1 bullish
Alvotech's 2025 adjusted EBITDA forecast was slashed by approximately 58% from its prior midpoint to a range of $130-$150 million.
So whatA massive reduction in profitability forecasts typically triggers severe downward valuation adjustments.
More negative than 99% of claims this week
The FDA issued a Complete Response Letter (CRL) citing manufacturing deficiencies at Alvotech's Reykjavik facility that must be resolved before AVT05 can be approved.
Continue reading
5 related stories
More negative than 96% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
More negative than 98% of claims this week
Alvotech's 2025 revenue guidance was lowered to $570-$600 million, approximately 10% below the previous midpoint.
More negative than 86% of claims this week
Law firm Hagens Berman has launched an investigation into whether Alvotech misled investors regarding its FDA interactions and the commercial prospects of AVT05.
More negative than 81% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company faces an investor investigation following a 33% stock crash caused by FDA manufacturing deficiencies and significantly lowered financial forecasts.
More negative than 80% of ticker scores this week
Mentioned as a company whose investors suffered losses due to allegedly misleading financial statements.
More negative than 80% of ticker scores this week
Mentioned as a company whose investors suffered losses due to allegedly misleading financial statements.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
4h ago
−4.4%
Price agrees with the score
$5.28 vs $5.52 close before publication (Nov 13) · not market-adjusted
ALVO chart →
